Literature DB >> 27316759

Prediction of hepatic cyst recurrence after minocycline hydrochloride aspiration sclerotherapy using cyst computed tomography values.

Takashi Iijima1, Tatsuya Suwabe1, Keiichi Sumida1, Noriko Hayami1, Koki Mise1, Junichi Hoshino1, Kenmei Takaichi1,2, Yoshifumi Ubara1,2.   

Abstract

AIM: Polycystic liver disease (PLD) occasionally leads to abdominal pain, distention, and discomfort due to massively enlarged cysts. Patients with a small number of large liver cysts, which correspond to Gigot's classification type 1 PLD, are reported to be good candidates for treatment by aspiration sclerotherapy. However, there is a 21% reported recurrence rate of an enlarged cyst. A rule to predict outcome of aspiration sclerotherapy is explored in this study.
METHODS: The medical records of patients with autosomal dominant polycystic kidney disease or isolated polycystic liver disease, who underwent minocycline hydrochloride cyst aspiration sclerotherapy for their symptomatic PLD, were retrospectively analyzed. Changes in the volume of cysts from before to 1 year after treatment were calculated using computed tomography (CT) images. Mean CT values of the largest planes of cysts were also calculated. Specific gravity and other laboratory parameters of aspirated cyst fluid were also retrospectively investigated.
RESULTS: In total, 12 patients were selected and 21 cysts were analyzed that received aspiration sclerotherapy. Mean CT values more than 13.34 HU were predictive for 1-year non-sustainability of a cyst volume of less than 30% compared with the volume prior to the therapy. Specific gravity had good positive correlation with mean CT value and other laboratory parameters indicating exudative properties were also high in recurred cysts.
CONCLUSIONS: The CT values of cysts may become an aid in appropriate selection of therapy in patients with symptomatic polycystic disease by distinguishing cysts that are resistant to aspiration sclerotherapy.
© 2016 The Japan Society of Hepatology.

Entities:  

Keywords:  isolated polycystic liver disease; polycystic kidney disease; puncture and aspiration

Year:  2016        PMID: 27316759     DOI: 10.1111/hepr.12763

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  2 in total

1.  Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease.

Authors:  Hiroki Mizuno; Junichi Hoshino; Tatsuya Suwabe; Keiichi Sumida; Akinari Sekine; Yoichi Oshima; Masahiko Oguro; Kyohei Kunizawa; Masahiro Kawada; Rikako Hiramatsu; Noriko Hayami; Eiko Hasegawa; Masayuki Yamanouchi; Naoki Sawa; Kenmei Takaichi; Yoshifumi Ubara
Journal:  Case Rep Nephrol Dial       Date:  2017-07-19

2.  Liver Transplant for Unusually Large Polycystic Liver Disease: Challenges and Pitfalls.

Authors:  Pablo Serrano Rodriguez; Alfred Sidney Barritt; David Allen Gerber; Chirag Sureshchandra Desai
Journal:  Case Rep Transplant       Date:  2018-02-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.